Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Eledon Pharmaceuticals

10/08/2026 12:36

Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Eledon Pharmaceuticals Inc is for a loss of 16 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $8.00, about 116.8% above its last closing price of $3.69
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.18
-0.18
-0.33
Missed
-80.8
Dec. 31 2026
-0.21
-0.20
-0.10
Beat
50.8
Sep. 30 2025
-0.28
-0.25
-0.21
Beat
16​
Jun. 30 2025
-0.20
-0.23
-0.13
Beat
43.5
​​Mar. 31 2025
-0.30
-0.30
-0.08
Beat
73.6
Dec. 31 2024
-0.31
-0.32
0.67
Beat
310.7​
Sep. 30 2024
-0.20
-0.31
-0.32
Missed
-1.6
Jun. 30 2024
-0.29
-0.30
-1.06
Missed
-249.4
This summary was machine generated August 10 at 11:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)